Analysts Are Bullish on Top Healthcare Stocks: Immutep (IMMP), Aethlon Medical (AEMD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immutep (IMMPResearch Report) and Aethlon Medical (AEMDResearch Report) with bullish sentiments.

Immutep (IMMP)

In a report released yesterday, Naureen Quibria from Maxim Group maintained a Buy rating on Immutep, with a price target of $8.00. The company’s shares closed last Wednesday at $3.84.

According to TipRanks.com, Quibria is a 2-star analyst with an average return of 1.3% and a 45.8% success rate. Quibria covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Fennec Pharmaceuticals, and Kazia Therapeutics.

Immutep has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.

See today’s best-performing stocks on TipRanks >>

Aethlon Medical (AEMD)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aethlon Medical, with a price target of $9.00. The company’s shares closed last Wednesday at $2.88, close to its 52-week low of $1.43.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 30.6% and a 36.2% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Achieve Life Sciences, and Phio Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aethlon Medical with a $10.00 average price target, representing a 239.0% upside. In a report issued on November 10, Maxim Group also reiterated a Buy rating on the stock with a $11.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IMMP: